• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/9/21 3:52:53 PM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ORMP alert in real time by email
    SC 13G/A 1 ea135034-sc13gaslager_oramed.htm AMENDMENT TO FORM SC 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

     

    ORAMED PHARMACEUTICALS INC.

    (Name of Issuer)

     

    Common Stock, par value $0.012 per share

    (Title of Class of Securities)

     

    68403P203

    (CUSIP Number)

     

    December 31, 2020

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)

     

    ☒Rule 13d-1(c)

     

    ☐Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 68403P203 13G/A Page 2 of 10 Pages

     

    1.

    Names of Reporting Persons

    Regals Capital Management LP

     

    2.

    Check the Appropriate Box if a Member of a Group

    (See Instructions)

     

    (a) ☐

    (b) ☐

     

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

    Delaware

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

     

    Sole Voting Power

     

    0

     

    6.

    Shared Voting Power

     

    1,344,123

     

    7.

    Sole Dispositive Power

     

    0

     

    8.

    Shared Dispositive Power

     

    1,344,123

     

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,344,123

     

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

    (See Instructions)

     

    ¨

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

    5.04%

     

     

    12.

    Type of Reporting Person (See Instructions)

     

    IN

     

     

     

     

     

    CUSIP No. 68403P203 13G/A Page 3 of 10 Pages

     

    1.

    Names of Reporting Persons

    Regals Fund LP

     

    2.

    Check the Appropriate Box if a Member of a Group

    (See Instructions)

     

    (a) ☐

    (b) ☐

     

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

    Delaware

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

     

    Sole Voting Power

     

    0

     

    6.

    Shared Voting Power

     

    1,344,123

     

    7.

    Sole Dispositive Power

     

    0

     

    8.

    Shared Dispositive Power

     

    1,344,123

     

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,344,123

     

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

    (See Instructions)

     

     

    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

     

    5.04%

     

     

    12.

    Type of Reporting Person (See Instructions)

     

    PN

     

     

     

     

     

    CUSIP No. 68403P203 13G/A Page 4 of 10 Pages

     

    1.

    Names of Reporting Persons

    David M. Slager

     

    2.

    Check the Appropriate Box if a Member of a Group

    (See Instructions)

     

    (a) ☐

    (b) ☐

     

    3.

    SEC Use Only

     

    4.

    Citizenship or Place of Organization

    Netherlands

     

     

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5.

     

    Sole Voting Power

     

    0

     

    6.

    Shared Voting Power

     

    1,344,123

     

    7.

    Sole Dispositive Power

     

    0

     

    8.

    Shared Dispositive Power

     

    1,344,123

     

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,344,123

     

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

    (See Instructions)

     

    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

     

    5.04%

     

     

    12.

    Type of Reporting Person (See Instructions)

     

    PN

     

     

     

     

     

    CUSIP No. 68403P203 13G/A Page 5 of 10 Pages

     

    This Amendment No. 1 is filed with respect to shares of Common Stock (as defined below) of Oramed Pharmaceuticals, Inc. beneficially owned by the Reporting Persons (as defined below) as of December 31, 2020, and amends and reinstates the Schedule 13G filed by the Reporting Persons on February 11, 2020.

     

    Item 1(a).Name of Issuer

     

    Oramed Pharmaceuticals Inc.

     

    Item 1(b).Address of Issuer’s Principal Executive Offices

     

    1185 Avenue of the Americas, Suite 228, New York, NY 10036.

     

    Item 2(a).Name of Person Filing

     

    This Schedule is filed on behalf of each of the following Reporting Persons:

     

    (1) Regals Capital Management LP (“Regals Management”)

     

    (2) Regals Fund LP (“Regals Fund”)

     

    (3) David M. Slager (“Mr. Slager”)

     

    Item 2(b).Address of Principal Business Offices or, if None, Residence

     

    The address of each Reporting Person is:

     

    c/o Regals Capital Management LP
    152 West 57th Street, 9th Floor
    New York, NY 10019

     

    Item 2(c).Citizenship

     

    Each of Regals Management and Regals Fund is a Delaware limited partnership.

     

    Mr. Slager is a citizen of The Netherlands.

     

    Item 2(d).Title of Class of Securities

     

    Common Stock.

     

    Item 2(e).CUSIP Number

     

    68403P203

     

    Item 3.If the statement is being filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the filing person is a:

     

    Not Applicable

     

     

     

     

    CUSIP No. 68403P203 13G/A Page 6 of 10 Pages

     

    Item 4.Ownership

     

    (a) Amount beneficially owned:

     

    Each Reporting Person may be deemed to beneficially own 1,344,123 shares of Common Stock of the Issuer, including 20,000 shares underlying currently exercisable shares. Regals Management is the investment manager of Regals Fund, the owner of record of the Common Stock reported in this Schedule. Mr. Slager is the managing member of the general partner of Regals Management. All investment decisions are made by Mr. Slager, and thus the power to vote or direct the votes of these shares of Common Stock, as well as the power to dispose or direct the disposition of such shares of common stock is held by Slager through Regals Management.

     

    (b) Percent of class:

     

    Each Reporting Person may be deemed to beneficially own 5.04% of the outstanding shares of Common Stock of the Issuer based upon 26,661,004 shares of Common Stock issued and outstanding as of January 14, 2021, as reported in Issuer’s Quarterly Report form 10-Q, filed with the Securities and Exchange Commission on January 14, 2021.

     

    (c) Number of shares as to which the person has:

     

    (i) Sole power to vote or to direct the vote:

     

    Regals Management:   0 
    Regals Fund:   0 
    Mr. Slager:   0 

     

    (ii) Shared power to vote or to direct the vote:

     

    Regals Management:   1,344,123 
    Regals Fund:   1,344,123 
    Mr. Slager:   1,344,123 

     

    (iii) Sole power to dispose or to direct the disposition of:

     

    Regals Management:   0 
    Regals Fund:   0 
    Mr. Slager:   0 

     

    (iv) Shared power to dispose or to direct the disposition of:

     

    Regals Management:   1,344,123 
    Regals Fund:   1,344,123 
    Mr. Slager:   1,344,123 

     

    Reference is made to Item 4(a) above as to the Issuer’s Common Stock that may be deemed to be beneficially owned by the Reporting Persons.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    Not Applicable

     

    Item 6.Ownership of More Than Five Percent on Behalf of Another Person

     

    Not Applicable

     

     

     

     

    CUSIP No. 68403P203 13G/A Page 7 of 10 Pages

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

     

    Not Applicable

     

    Item 8.Identification and Classification of Members of the Group

     

    Not Applicable

     

    Item 9.Notice of Dissolution of Group

     

    Not Applicable

     

    Item 10.Certification

     

    By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

    CUSIP No. 68403P203 13G/A Page 8 of 10 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, each Reporting Person certifies that the information set forth in this statement is true, complete and correct.

     

    Dated:  February 9, 2021 Regals Capital Management LP
      By: Regals Capital Holdings LLC, its general partner
       
      /s/ David M. Slager
      Name: David M. Slager
      Title: Managing Member
       
    Dated:  February 9, 2021 Regals Fund LP
      By: Regals Fund GP LLC, its general partner
       
      /s/ David M. Slager
      Name: David M. Slager
      Title: Managing Member
       
    Dated:  February 9, 2021 David M. Slager
       
      /s/ David M. Slager
      Name: David M. Slager

     

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

      

     

     

     

    CUSIP No. 68403P203 13G/A Page 9 of 10 Pages

     

    EXHIBIT INDEX

     

    Exhibit   Description
         
    99.1   Agreement of Joint Filing. (Filed herewith)

     

     

    Get the next $ORMP alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ORMP

    DatePrice TargetRatingAnalyst
    1/12/2023$30.00 → $3.00Buy → Hold
    Canaccord Genuity
    2/18/2022$20.00Overweight
    Cantor Fitzgerald
    11/30/2021$17.00 → $32.00Buy
    HC Wainwright & Co.
    11/29/2021$17.00 → $32.00Buy
    HC Wainwright & Co.
    11/2/2021$20.00 → $35.00Buy
    Aegis Capital
    7/29/2021$27.00 → $30.00Buy
    Canaccord Genuity
    More analyst ratings

    $ORMP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Oramed Reports Fiscal Third Quarter 2025 Financial Results

    Strong Nine-Month Performance Driven by Strategic Investment Portfolio; Total Assets Increase 42% to $220.5 Million NEW YORK, Nov. 17, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection, today announced its unaudited financial results for the nine months ended September 30, 2025. Nine-Month Period 2025 Financial Highlights: Net income (pre-tax) of $65.0 million, compared to a net loss of $6.1 million in the same period last yearCompleted

    11/17/25 8:56:00 AM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS

    NEW YORK, Nov. 17, 2025 /PRNewswire/ -- The Board of Directors of Oramed Pharmaceuticals Inc. (the "Company") announced today that it has unanimously adopted a Rights Agreement, dated November 17, 2025 (the "Rights Plan"), by and between the Company and Continental Stock Transfer & Trust Company, as rights agent, and declared a dividend of one common stock purchase right (a "Right") on each outstanding share of its common stock, par value $0.012 per share (the "Common Stock"), of the Company.  The Rights are designed to assure that all stockholders of the Company receive fair and equal treatment in the event of a hostile takeover of the Company, to guard against tactics designed to gain cont

    11/17/25 8:50:00 AM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives

    Oramed Advancing Oral Insulin Program Independently; Announces Launch of New U.S. Trial Diversified Investment Portfolio Delivers Strong Returns Company Accelerating Growth Through Strategic Partnerships, Innovation, and Value-Driven ExpansionCompany Reaffirms Commitment to Rewarding Shareholders, Including Plans for a One-Time DividendNEW YORK, Oct. 23, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) ("Oramed" or the "Company" or "we"), a clinical-stage pharmaceutical company, today issued a Letter to Shareholders from its President and Chief Executive Officer, Nadav Kidron. Dear Shareholders, I am pleased to share with you some of the significant developments w

    10/23/25 8:55:00 AM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORMP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mayer Arie was granted 36,975 shares, increasing direct ownership by 38% to 133,109 units (SEC Form 4)

    4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)

    6/9/25 4:08:35 PM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Aghion Daniel was granted 38,371 shares, increasing direct ownership by 99% to 77,191 units (SEC Form 4)

    4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)

    6/9/25 4:08:22 PM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Reznick Yehuda was granted 38,370 shares, increasing direct ownership by 126% to 68,930 units (SEC Form 4)

    4 - ORAMED PHARMACEUTICALS INC. (0001176309) (Issuer)

    6/9/25 4:08:06 PM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORMP
    SEC Filings

    View All

    Oramed Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)

    11/17/25 9:05:55 AM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-A12B filed by Oramed Pharmaceuticals Inc.

    8-A12B - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)

    11/17/25 8:51:43 AM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oramed Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

    8-K - ORAMED PHARMACEUTICALS INC. (0001176309) (Filer)

    11/17/25 8:50:42 AM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORMP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oramed Pharmaceuticals downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Oramed Pharmaceuticals from Buy to Hold and set a new price target of $3.00 from $30.00 previously

    1/12/23 7:54:45 AM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Oramed Pharmaceuticals with a new price target

    Cantor Fitzgerald initiated coverage of Oramed Pharmaceuticals with a rating of Overweight and set a new price target of $20.00

    2/18/22 6:43:35 AM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Oramed Pharmaceuticals with a new price target

    HC Wainwright & Co. reiterated coverage of Oramed Pharmaceuticals with a rating of Buy and set a new price target of $32.00 from $17.00 previously

    11/30/21 7:36:11 AM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORMP
    Leadership Updates

    Live Leadership Updates

    View All

    Oramed Appoints Ben Shapiro to its Board of Directors

    NEW YORK, May 1, 2023 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) ("Oramed" or the "Company") (www.oramed.com) announced today the appointment of Mr. Benjamin Shapiro to its Board of Directors effective May 1, 2023. The Board determined that Mr. Shapiro qualifies as an independent director under the listing rules of the Nasdaq Capital Market.     Ben Shapiro is a successful entrepreneur and business professional who co-founded The Daily Wire, a successful, industry leading, international media outlet in June 2015. Since May 2015, he is host of "The Ben Shapiro Show," a popular podcast, and he is the author of numerous New York Times best-selling books. Mr. Shapiro earned

    5/1/23 4:45:00 PM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oramed Appoints Dr. Anne Peters to its Scientific Advisory Board

    NEW YORK, June 1, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the appointment of Anne Peters, MD, to its Scientific Advisory Board. Anne Peters, MD, is Professor of Medicine at the Keck School of Medicine of USC and Director of the USC Clinical Diabetes Programs. Dr. Peters earned her medical degree from the Pritzker School of Medicine at the University of Chicago and performed an internal medicine residency at Stanford University and an endocrinology fellowship at Cedars-Sinai Medical Center. She previously directed the clinical diabetes progra

    6/1/22 7:55:00 AM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oramed Pharmaceuticals Appoints Chief Legal Officer

    NEW YORK, Dec. 8, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the appointment of Netanel Derovan to serve as Chief Legal Officer (General Counsel) and Company Secretary, effective January 9, 2022. Mr. Derovan will oversee Oramed's legal and corporate strategy affairs and provide strategic guidance to the executive team and Board of Directors. "We are very pleased to welcome Netanel Derovan as Oramed's Chief Legal Officer. Netanel's business-minded approach, legal acumen and strong operational skills will be instrumental to Oramed

    12/8/21 7:30:00 AM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORMP
    Financials

    Live finance-specific insights

    View All

    Oramed Reports Fiscal Third Quarter 2025 Financial Results

    Strong Nine-Month Performance Driven by Strategic Investment Portfolio; Total Assets Increase 42% to $220.5 Million NEW YORK, Nov. 17, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection, today announced its unaudited financial results for the nine months ended September 30, 2025. Nine-Month Period 2025 Financial Highlights: Net income (pre-tax) of $65.0 million, compared to a net loss of $6.1 million in the same period last yearCompleted

    11/17/25 8:56:00 AM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS

    NEW YORK, Nov. 17, 2025 /PRNewswire/ -- The Board of Directors of Oramed Pharmaceuticals Inc. (the "Company") announced today that it has unanimously adopted a Rights Agreement, dated November 17, 2025 (the "Rights Plan"), by and between the Company and Continental Stock Transfer & Trust Company, as rights agent, and declared a dividend of one common stock purchase right (a "Right") on each outstanding share of its common stock, par value $0.012 per share (the "Common Stock"), of the Company.  The Rights are designed to assure that all stockholders of the Company receive fair and equal treatment in the event of a hostile takeover of the Company, to guard against tactics designed to gain cont

    11/17/25 8:50:00 AM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives

    Oramed Advancing Oral Insulin Program Independently; Announces Launch of New U.S. Trial Diversified Investment Portfolio Delivers Strong Returns Company Accelerating Growth Through Strategic Partnerships, Innovation, and Value-Driven ExpansionCompany Reaffirms Commitment to Rewarding Shareholders, Including Plans for a One-Time DividendNEW YORK, Oct. 23, 2025 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) ("Oramed" or the "Company" or "we"), a clinical-stage pharmaceutical company, today issued a Letter to Shareholders from its President and Chief Executive Officer, Nadav Kidron. Dear Shareholders, I am pleased to share with you some of the significant developments w

    10/23/25 8:55:00 AM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ORMP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Oramed Pharmaceuticals Inc.

    SC 13G - ORAMED PHARMACEUTICALS INC. (0001176309) (Subject)

    9/16/24 4:42:03 PM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Oramed Pharmaceuticals Inc.

    SC 13D - ORAMED PHARMACEUTICALS INC. (0001176309) (Subject)

    3/22/24 9:30:27 PM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Oramed Pharmaceuticals Inc. (Amendment)

    SC 13D/A - ORAMED PHARMACEUTICALS INC. (0001176309) (Subject)

    9/2/21 4:49:56 PM ET
    $ORMP
    Biotechnology: Pharmaceutical Preparations
    Health Care